Kandalaft LE - Search Results

1

Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development.

Kreidieh FY, Tawbi HA, Alexaki A, Borghaei H, Kandalaft LE. Kreidieh FY, et al. Among authors: kandalaft le. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e391278. doi: 10.1200/EDBK_391278. Am Soc Clin Oncol Educ Book. 2023. PMID: 37364224 Free article.

2

Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) exhibits an inhibitory role on tumorigenesis.

Kandalaft LE, Zudaire E, Portal-Núñez S, Cuttitta F, Jakowlew SB. Kandalaft LE, et al. Carcinogenesis. 2008 Jun;29(6):1282-9. doi: 10.1093/carcin/bgn087. Epub 2008 Apr 1. Carcinogenesis. 2008. PMID: 18381359 Free PMC article.

3

Clinical translation section: accelerating the pace from bench to bedside.

Kandalaft LE, Coukos G. Kandalaft LE, et al. J Transl Med. 2011 Jul 21;9:116. doi: 10.1186/1479-5876-9-116. J Transl Med. 2011. PMID: 25928255 Free PMC article. No abstract available.

4

Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures.

Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M. Campbell L, et al. Among authors: kandalaft le. J Pharmacol Exp Ther. 2003 Jan;304(1):441-52. doi: 10.1124/jpet.102.042994. J Pharmacol Exp Ther. 2003. PMID: 12490621

5

Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers.

Siccardi D, Kandalaft LE, Gumbleton M, McGuigan C. Siccardi D, et al. Among authors: kandalaft le. J Pharmacol Exp Ther. 2003 Dec;307(3):1112-9. doi: 10.1124/jpet.103.056135. Epub 2003 Oct 13. J Pharmacol Exp Ther. 2003. PMID: 14557377

6

Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung.

Sakagami M, Omidi Y, Campbell L, Kandalaft LE, Morris CJ, Barar J, Gumbleton M. Sakagami M, et al. Among authors: kandalaft le. Pharm Res. 2006 Feb;23(2):270-9. doi: 10.1007/s11095-005-9226-0. Epub 2006 Jan 1. Pharm Res. 2006. PMID: 16382279

7

Immunotherapy for ovarian cancer: what's next?

Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Kandalaft LE, et al. J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. J Clin Oncol. 2011. PMID: 21079136 Free PMC article. Review.

8

Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Ophir E, et al. Among authors: kandalaft le. Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Biochim Biophys Acta. 2016. PMID: 26241169 Review.

9

Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Mastelic-Gavillet B, et al. Among authors: kandalaft le. Front Immunol. 2019 Apr 11;10:766. doi: 10.3389/fimmu.2019.00766. eCollection 2019. Front Immunol. 2019. PMID: 31031762 Free PMC article. Review.

10

Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.

Ahmed R, Sayegh N, Graciotti M, Kandalaft LE. Ahmed R, et al. Among authors: kandalaft le. Curr Opin Biotechnol. 2020 Oct;65:142-155. doi: 10.1016/j.copbio.2020.02.009. Epub 2020 Mar 30. Curr Opin Biotechnol. 2020. PMID: 32240923 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters